Myocardial Cell Preservation from Potential Cardiotoxic Drugs: The Role of Nanotechnologies
Cardiotoxic therapies, whether chemotherapeutic or antibiotic, represent a burden for patients who may need to interrupt life-saving treatment because of serious complications. Cardiotoxicity is a broad term, spanning from forms of heart failure induction, particularly left ventricular systolic dysf...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-12-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/15/1/87 |
| _version_ | 1797437835132796928 |
|---|---|
| author | Adelaide Iervolino Luigi Spadafora Cristiano Spadaccio Valentina Iervolino Giuseppe Biondi Zoccai Felicita Andreotti |
| author_facet | Adelaide Iervolino Luigi Spadafora Cristiano Spadaccio Valentina Iervolino Giuseppe Biondi Zoccai Felicita Andreotti |
| author_sort | Adelaide Iervolino |
| collection | DOAJ |
| description | Cardiotoxic therapies, whether chemotherapeutic or antibiotic, represent a burden for patients who may need to interrupt life-saving treatment because of serious complications. Cardiotoxicity is a broad term, spanning from forms of heart failure induction, particularly left ventricular systolic dysfunction, to induction of arrhythmias. Nanotechnologies emerged decades ago. They offer the possibility to modify the profiles of potentially toxic drugs and to abolish off-target side effects thanks to more favorable pharmacokinetics and dynamics. This relatively modern science encompasses nanocarriers (e.g., liposomes, niosomes, and dendrimers) and other delivery systems applicable to real-life clinical settings. We here review selected applications of nanotechnology to the fields of pharmacology and cardio-oncology. Heart tissue-sparing co-administration of nanocarriers bound to chemotherapeutics (such as anthracyclines and platinum agents) are discussed based on recent studies. Nanotechnology applications supporting the administration of potentially cardiotoxic oncological target therapies, antibiotics (especially macrolides and fluoroquinolones), or neuroactive agents are also summarized. The future of nanotechnologies includes studies to improve therapeutic safety and to encompass a broader range of pharmacological agents. The field merits investments and research, as testified by its exponential growth. |
| first_indexed | 2024-03-09T11:28:22Z |
| format | Article |
| id | doaj.art-4aa3eece8aa24ee0be74ed28034f8a7d |
| institution | Directory Open Access Journal |
| issn | 1999-4923 |
| language | English |
| last_indexed | 2024-03-09T11:28:22Z |
| publishDate | 2022-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj.art-4aa3eece8aa24ee0be74ed28034f8a7d2023-11-30T23:57:28ZengMDPI AGPharmaceutics1999-49232022-12-011518710.3390/pharmaceutics15010087Myocardial Cell Preservation from Potential Cardiotoxic Drugs: The Role of NanotechnologiesAdelaide Iervolino0Luigi Spadafora1Cristiano Spadaccio2Valentina Iervolino3Giuseppe Biondi Zoccai4Felicita Andreotti5Department of Clinical Medicine and Surgery, Federico II University, 80131 Naples, ItalyDepartment of Clinical, Internal Medicine, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, 00189 Rome, ItalyDepartment of Cardiovascular Surgery, Mayo Clinic, Rochester, MN 55905, USACentre Hospitalier Universitaire Henri-Mondor, Faculté de Médecine, Université Paris Est Créteil, 94000 Créteil, FranceDepartment of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, 00189 Rome, ItalyDepartment of Cardiovascular Sciences, Fondazione Policlinico Universitario A Gemelli IRCCS, 00168 Rome, ItalyCardiotoxic therapies, whether chemotherapeutic or antibiotic, represent a burden for patients who may need to interrupt life-saving treatment because of serious complications. Cardiotoxicity is a broad term, spanning from forms of heart failure induction, particularly left ventricular systolic dysfunction, to induction of arrhythmias. Nanotechnologies emerged decades ago. They offer the possibility to modify the profiles of potentially toxic drugs and to abolish off-target side effects thanks to more favorable pharmacokinetics and dynamics. This relatively modern science encompasses nanocarriers (e.g., liposomes, niosomes, and dendrimers) and other delivery systems applicable to real-life clinical settings. We here review selected applications of nanotechnology to the fields of pharmacology and cardio-oncology. Heart tissue-sparing co-administration of nanocarriers bound to chemotherapeutics (such as anthracyclines and platinum agents) are discussed based on recent studies. Nanotechnology applications supporting the administration of potentially cardiotoxic oncological target therapies, antibiotics (especially macrolides and fluoroquinolones), or neuroactive agents are also summarized. The future of nanotechnologies includes studies to improve therapeutic safety and to encompass a broader range of pharmacological agents. The field merits investments and research, as testified by its exponential growth.https://www.mdpi.com/1999-4923/15/1/87delivery systemsnanoparticlesliposomesdendrimerscardiotoxicitycardio-oncology |
| spellingShingle | Adelaide Iervolino Luigi Spadafora Cristiano Spadaccio Valentina Iervolino Giuseppe Biondi Zoccai Felicita Andreotti Myocardial Cell Preservation from Potential Cardiotoxic Drugs: The Role of Nanotechnologies Pharmaceutics delivery systems nanoparticles liposomes dendrimers cardiotoxicity cardio-oncology |
| title | Myocardial Cell Preservation from Potential Cardiotoxic Drugs: The Role of Nanotechnologies |
| title_full | Myocardial Cell Preservation from Potential Cardiotoxic Drugs: The Role of Nanotechnologies |
| title_fullStr | Myocardial Cell Preservation from Potential Cardiotoxic Drugs: The Role of Nanotechnologies |
| title_full_unstemmed | Myocardial Cell Preservation from Potential Cardiotoxic Drugs: The Role of Nanotechnologies |
| title_short | Myocardial Cell Preservation from Potential Cardiotoxic Drugs: The Role of Nanotechnologies |
| title_sort | myocardial cell preservation from potential cardiotoxic drugs the role of nanotechnologies |
| topic | delivery systems nanoparticles liposomes dendrimers cardiotoxicity cardio-oncology |
| url | https://www.mdpi.com/1999-4923/15/1/87 |
| work_keys_str_mv | AT adelaideiervolino myocardialcellpreservationfrompotentialcardiotoxicdrugstheroleofnanotechnologies AT luigispadafora myocardialcellpreservationfrompotentialcardiotoxicdrugstheroleofnanotechnologies AT cristianospadaccio myocardialcellpreservationfrompotentialcardiotoxicdrugstheroleofnanotechnologies AT valentinaiervolino myocardialcellpreservationfrompotentialcardiotoxicdrugstheroleofnanotechnologies AT giuseppebiondizoccai myocardialcellpreservationfrompotentialcardiotoxicdrugstheroleofnanotechnologies AT felicitaandreotti myocardialcellpreservationfrompotentialcardiotoxicdrugstheroleofnanotechnologies |